Coronado-Malagón M, Gómez-Vargas JI, Espinoza-Peralta D, Arce-Salinas A

Language: Spanish
References: 13
Page: 269-272
PDF size: 59.44 Kb.

ABSTRACT

Background: Pre-diabetic Latino subjects have shown higher incidence of type 2 diabetes mellitus (DM2) compared with other populations. The incidence is unknown in the Mexican population. Our aim was to identify the annual incidence of DM2 among a Mexican pre-diabetic population.
Methods: An inception cohort of healthy Mexican patients was followed from 2001 to 2006. Those who fulfilled diagnosis of DM2 (ADA criteria) were registered at one and 2 years of follow-up among pre-diabetic and normoglucemic individuals. We compared relevant variables between both groups, those who developed diabetes and those who did not.
Results: 656 subjects were included; at one year, 14 patients were diagnosed with DM2, 11 among pre-diabetics, incidence of 4.5 %; 3 among normoglucemic subjects, incidence of 0.72 %. The relative risk for the development of DM2 in the pre-diabetic group was 7.7 (IC95 % 2.1-27.9), and among the normoglucemic group of 1.04 (IC95 % 1.02-1.08). At the 2^nd year, DM2 incidence was 7.6 % in pre-diabetics, and 0.6 % in normoglucemics. Risk factors associated were higher fast glucose and greater BMI.
Conclusions: We found a constant annual incidence of DM2 among prediabetics of 6 cases per 100 patient/year in follow-up. Higher fast glucose determinations and greater BMI are the main determinants for DM2 development.

REFERENCES

1. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.

2. Aguilar-Salinas CA, Velázquez-Monroy O, Gómez-Pérez FJ, González-Chávez A, Esqueda AL, Molina-Cuevas V, et al. Characteristics of patients with type 2 diabetes in Mexico: Results from a large population based nationwide survey. Diabetes Care 2003;26:2021-2026.

3. Secretaría de Salud. Estadísticas vitales de México. 2007. Disponible en http:// sinais.salud.gob.mx/descargas/xls/diezprincausasmort2007_CNEGySR.xls

4. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravossin F, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulindependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988-1992.

5. Eldin WS, Emara M, Shoker A. Prediabetes: a must to recognise disease state. Int J Clin Pract 2008;62:642-648.

6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30(Suppl 1):S42-S47.

7. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-759.

8. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Llanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.

9. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: 393-403.

10. Rasmussen SS, Glümer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year followup in the ADDITION study, Denmark. Diabetologia 2008;51:249-257.

11. Ferrannini E, Massari M, Nannipieri M, Natali A, López-Ridaura R, González-Villalpando C. Plasma glucose levels as predictors of diabetes: The Mexico City diabetes study. Diabetologia 2009;52:818-824.

12. Chen KT, Chen CJ, Gregg EW, Imperatore G, Narayan KM. Impaired fasting glucose and risk of diabetes in Taiwan: follow-up over 3 years. Diabetes Res Clin Pract 2003;60:177-182.

13. Edelstein SL, Knowler WC, Bain RP, Andrés R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701-710.